Sofosbuvir/daclatasvir combination could be produced for $200 per hepatitis C cure
Published: 14 December 2015
Excerpts ONLY - copy or select link right click via browser above and go there to read full article.
"Month-by-month tracking of the prices paid in India for the chemicals used to make hepatitis C direct-acting antivirals shows that it is now possible to make and sell a combination of drugs to cure hepatitis C for less than $200, Dr Andrew Hill of Liverpool University told the Second European HIV Hepatitis Co-infection Conference in London last week".
"In the case of sofosbuvir, they found that even assuming a 50% profit margin for the manufacturer to cover capital investment and return to shareholders, it would now be possible to sell a 12-week course of the drug for $178."
"These costings suggest that it would be possible to market a pan-genotypic combination of sofosbuvir and daclatasvir for no more than $200. But many of the middle-income countries with a high burden of hepatitis C, such as China, Brazil, Ukraine and Latin America, will continue to be excluded by the terms of voluntary licensing agreements from obtaining Indian generics – unless they pursue compulsory licensing. "
"In the case of hepatitis C treatment, people could take matters into their own hands without waiting for governments."